drugset
drugset / Trial / NCT05673876

A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)

NCT05673876 ↗

Phase 1 Completed 7 enrolled Genentech, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose of the study is to assess the safety and pharmacokinetics (PK) of GDC-8264 in participants with acute graft-versus-host disease (aGVHD).

Timeline

Start
2023-04-06
Primary completion
2024-01-15
Completion
2024-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject FLIZASERTIB Small molecule 35 mg Oral
Subject FLIZASERTIB Small molecule 75 mg Oral

Indications

acute graft versus host disease